Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy
Identifieur interne : 000E30 ( Main/Exploration ); précédent : 000E29; suivant : 000E31Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy
Auteurs : P. Hadji [Allemagne] ; M. Ziller ; D. G. Kieback ; W. Dornoff ; H. W. Tessen [Allemagne] ; T. Menschik [France] ; J. Kuck [Allemagne] ; F. Melchert ; A. Hasenburg [Allemagne]Source :
- Annals of Oncology [ 0923-7534 ] ; 2009-02-13.
Descripteurs français
- Pascal (Inist)
- Wicri :
- geographic : Allemagne.
- topic : Prospective.
English descriptors
- KwdEn :
Abstract
Background: Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with aromatase inhibitors may be associated with increased bone loss. Patients and methods: Two hundred patients were randomised to receive exemestane or tamoxifen as adjuvant treatment of hormone receptor-positive breast cancer. Bone mineral density (BMD) was assessed by dual-energy X-ray absorptiometry at baseline and after 6 and 12 months treatment. Results: One hundred and sixty-one patients were assessable. Tamoxifen treatment resulted in a 0.5% increase from baseline in BMD at the spine, which was maintained at 12 months. Exemestane-treated patients experienced a 2.6% decrease from baseline in BMD at the spine at 6 months and a further 0.2% decrease at 12 months. There were significant differences in the changes in BMD between tamoxifen and exemestane at 6 and 12 months (P0.0026 and P0.0008, respectively). The mean changes in BMD from baseline at the total hip were also significantly different between exemestane and tamoxifen at 6 and 12 months (P 0.0009 and P0.04, respectively). There was no difference between tamoxifen and exemestane in mean changes in BMD from baseline at the femoral neck. Conclusions: Exemestane treatment resulted in an increase in bone loss at 6 months; bone loss stabilised after 6- to 12-month treatment.
Url:
DOI: 10.1093/annonc/mdn762
Affiliations:
- Allemagne, France
- Bade-Wurtemberg, Berlin, District de Fribourg-en-Brisgau, Île-de-France
- Berlin, Fribourg-en-Brisgau, Paris
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001B53
- to stream Istex, to step Curation: 001A36
- to stream Istex, to step Checkpoint: 000377
- to stream Main, to step Merge: 000F04
- to stream PascalFrancis, to step Corpus: 000674
- to stream PascalFrancis, to step Curation: 000732
- to stream PascalFrancis, to step Checkpoint: 000529
- to stream Main, to step Merge: 001085
- to stream Main, to step Curation: 000E30
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy</title><author><name sortKey="Hadji, P" sort="Hadji, P" uniqKey="Hadji P" first="P." last="Hadji">P. Hadji</name></author><author><name sortKey="Ziller, M" sort="Ziller, M" uniqKey="Ziller M" first="M." last="Ziller">M. Ziller</name></author><author><name sortKey="Kieback, D G" sort="Kieback, D G" uniqKey="Kieback D" first="D. G." last="Kieback">D. G. Kieback</name></author><author><name sortKey="Dornoff, W" sort="Dornoff, W" uniqKey="Dornoff W" first="W." last="Dornoff">W. Dornoff</name></author><author><name sortKey="Tessen, H W" sort="Tessen, H W" uniqKey="Tessen H" first="H. W." last="Tessen">H. W. Tessen</name></author><author><name sortKey="Menschik, T" sort="Menschik, T" uniqKey="Menschik T" first="T." last="Menschik">T. Menschik</name></author><author><name sortKey="Kuck, J" sort="Kuck, J" uniqKey="Kuck J" first="J." last="Kuck">J. Kuck</name></author><author><name sortKey="Melchert, F" sort="Melchert, F" uniqKey="Melchert F" first="F." last="Melchert">F. Melchert</name></author><author><name sortKey="Hasenburg, A" sort="Hasenburg, A" uniqKey="Hasenburg A" first="A." last="Hasenburg">A. Hasenburg</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:18C4680D33EFE385185847F4B93A7102B6E899C4</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1093/annonc/mdn762</idno><idno type="url">https://api.istex.fr/document/18C4680D33EFE385185847F4B93A7102B6E899C4/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001B53</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001B53</idno><idno type="wicri:Area/Istex/Curation">001A36</idno><idno type="wicri:Area/Istex/Checkpoint">000377</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000377</idno><idno type="wicri:doubleKey">0923-7534:2009:Hadji P:effects:of:exemestane</idno><idno type="wicri:Area/Main/Merge">000F04</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:09-0309205</idno><idno type="wicri:Area/PascalFrancis/Corpus">000674</idno><idno type="wicri:Area/PascalFrancis/Curation">000732</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000529</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000529</idno><idno type="wicri:doubleKey">0923-7534:2009:Hadji P:effects:of:exemestane</idno><idno type="wicri:Area/Main/Merge">001085</idno><idno type="wicri:Area/Main/Curation">000E30</idno><idno type="wicri:Area/Main/Exploration">000E30</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy</title><author><name sortKey="Hadji, P" sort="Hadji, P" uniqKey="Hadji P" first="P." last="Hadji">P. Hadji</name><affiliation></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Allemagne</country></affiliation></author><author><name sortKey="Ziller, M" sort="Ziller, M" uniqKey="Ziller M" first="M." last="Ziller">M. Ziller</name><affiliation><wicri:noCountry code="subField">Marburg</wicri:noCountry></affiliation></author><author><name sortKey="Kieback, D G" sort="Kieback, D G" uniqKey="Kieback D" first="D. G." last="Kieback">D. G. Kieback</name><affiliation><wicri:noCountry code="subField">Aue</wicri:noCountry></affiliation></author><author><name sortKey="Dornoff, W" sort="Dornoff, W" uniqKey="Dornoff W" first="W." last="Dornoff">W. Dornoff</name><affiliation><wicri:noCountry code="subField">Trier</wicri:noCountry></affiliation></author><author><name sortKey="Tessen, H W" sort="Tessen, H W" uniqKey="Tessen H" first="H. W." last="Tessen">H. W. Tessen</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Onkologische Schwerpunktpraxis, Goslar</wicri:regionArea><wicri:noRegion>Goslar</wicri:noRegion><wicri:noRegion>Goslar</wicri:noRegion></affiliation></author><author><name sortKey="Menschik, T" sort="Menschik, T" uniqKey="Menschik T" first="T." last="Menschik">T. Menschik</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Pfizer, Specialty Brand Team Europe, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Kuck, J" sort="Kuck, J" uniqKey="Kuck J" first="J." last="Kuck">J. Kuck</name><affiliation wicri:level="3"><country>Allemagne</country><placeName><settlement type="city">Berlin</settlement><region type="land" nuts="2">Berlin</region></placeName><wicri:orgArea>Independent Clinical Research Consulting, Blschestrasse</wicri:orgArea></affiliation></author><author><name sortKey="Melchert, F" sort="Melchert, F" uniqKey="Melchert F" first="F." last="Melchert">F. Melchert</name><affiliation><wicri:noCountry code="subField">Mannheim</wicri:noCountry></affiliation></author><author><name sortKey="Hasenburg, A" sort="Hasenburg, A" uniqKey="Hasenburg A" first="A." last="Hasenburg">A. Hasenburg</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Freiburg University, Frauenklinik, Freiburg</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Fribourg-en-Brisgau</region><settlement type="city">Fribourg-en-Brisgau</settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Oncology</title><idno type="ISSN">0923-7534</idno><idno type="eISSN">1569-8041</idno><imprint><publisher>Oxford University Press</publisher><date type="published" when="2009-02-13">2009-02-13</date><biblScope unit="volume">20</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="1203">1203</biblScope><biblScope unit="page" to="1209">1209</biblScope></imprint><idno type="ISSN">0923-7534</idno></series><idno type="istex">18C4680D33EFE385185847F4B93A7102B6E899C4</idno><idno type="DOI">10.1093/annonc/mdn762</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0923-7534</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic agent</term><term>Aromatase inhibitor</term><term>Bone</term><term>Bone mineral density</term><term>Breast cancer</term><term>Clinical trial</term><term>Early</term><term>Exemestane</term><term>Fracture</term><term>Germany</term><term>Health</term><term>Osteoporosis</term><term>Prospective</term><term>Randomization</term><term>Tamoxifene</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Allemagne</term><term>Anticancéreux</term><term>Cancer du sein</term><term>Densité minérale osseuse</term><term>Essai clinique</term><term>Exémestane</term><term>Fracture</term><term>Inhibiteur de l'aromatase</term><term>Os</term><term>Ostéoporose</term><term>Prospective</term><term>Précoce</term><term>Randomisation</term><term>Santé</term><term>Tamoxifène</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Allemagne</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Prospective</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract">Background: Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with aromatase inhibitors may be associated with increased bone loss. Patients and methods: Two hundred patients were randomised to receive exemestane or tamoxifen as adjuvant treatment of hormone receptor-positive breast cancer. Bone mineral density (BMD) was assessed by dual-energy X-ray absorptiometry at baseline and after 6 and 12 months treatment. Results: One hundred and sixty-one patients were assessable. Tamoxifen treatment resulted in a 0.5% increase from baseline in BMD at the spine, which was maintained at 12 months. Exemestane-treated patients experienced a 2.6% decrease from baseline in BMD at the spine at 6 months and a further 0.2% decrease at 12 months. There were significant differences in the changes in BMD between tamoxifen and exemestane at 6 and 12 months (P0.0026 and P0.0008, respectively). The mean changes in BMD from baseline at the total hip were also significantly different between exemestane and tamoxifen at 6 and 12 months (P 0.0009 and P0.04, respectively). There was no difference between tamoxifen and exemestane in mean changes in BMD from baseline at the femoral neck. Conclusions: Exemestane treatment resulted in an increase in bone loss at 6 months; bone loss stabilised after 6- to 12-month treatment.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>France</li></country><region><li>Bade-Wurtemberg</li><li>Berlin</li><li>District de Fribourg-en-Brisgau</li><li>Île-de-France</li></region><settlement><li>Berlin</li><li>Fribourg-en-Brisgau</li><li>Paris</li></settlement></list><tree><noCountry><name sortKey="Dornoff, W" sort="Dornoff, W" uniqKey="Dornoff W" first="W." last="Dornoff">W. Dornoff</name><name sortKey="Kieback, D G" sort="Kieback, D G" uniqKey="Kieback D" first="D. G." last="Kieback">D. G. Kieback</name><name sortKey="Melchert, F" sort="Melchert, F" uniqKey="Melchert F" first="F." last="Melchert">F. Melchert</name><name sortKey="Ziller, M" sort="Ziller, M" uniqKey="Ziller M" first="M." last="Ziller">M. Ziller</name></noCountry><country name="Allemagne"><noRegion><name sortKey="Hadji, P" sort="Hadji, P" uniqKey="Hadji P" first="P." last="Hadji">P. Hadji</name></noRegion><name sortKey="Hasenburg, A" sort="Hasenburg, A" uniqKey="Hasenburg A" first="A." last="Hasenburg">A. Hasenburg</name><name sortKey="Kuck, J" sort="Kuck, J" uniqKey="Kuck J" first="J." last="Kuck">J. Kuck</name><name sortKey="Tessen, H W" sort="Tessen, H W" uniqKey="Tessen H" first="H. W." last="Tessen">H. W. Tessen</name></country><country name="France"><region name="Île-de-France"><name sortKey="Menschik, T" sort="Menschik, T" uniqKey="Menschik T" first="T." last="Menschik">T. Menschik</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Rhénanie/explor/UnivTrevesV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E30 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000E30 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Rhénanie
|area= UnivTrevesV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:18C4680D33EFE385185847F4B93A7102B6E899C4
|texte= Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy
}}
| This area was generated with Dilib version V0.6.31. |  |